quinazolines has been researched along with Cancer of Stomach in 137 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.73) | 18.2507 |
| 2000's | 35 (25.55) | 29.6817 |
| 2010's | 88 (64.23) | 24.3611 |
| 2020's | 13 (9.49) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, J; Lei, F; Li, J; Liang, Z; Shi, T; Wang, Y; Wang, Z; Yang, X; Zhang, H | 1 |
| Han, R; Huang, Y; Wang, Z; Yan, Y; Yang, Q; Zhang, X | 1 |
| He, N; Jiao, ZY; Li, LS; Ma, ZJ; Sun, RF; Yu, ZY; Zhang, GY | 1 |
| Chen, X; Dai, J; Hu, C; Lin, X; Yu, J | 1 |
| Huang, J; Li, J; Shen, L; Su, WG; Wang, ZX; Xu, RH; Zhang, DS; Zhang, Y | 1 |
| Hou, R; Li, S; Liu, D; Ma, W; Meng, B; Ren, T; Shi, M; Wang, X; Xu, Z; Zhao, X; Zheng, J | 1 |
| Cui, H; Dong, Z; Hou, J; Ke, X; Wang, F; Yang, L; Yin, C; Zhang, K; Zhang, R; Zhong, X | 1 |
| Anthoney, DA; Collins, L; Eatock, M; Elhussein, L; Falk, S; Goff, M; Lord, SR; Love, S; Middleton, MR; Moschandreas, J; Thomas, A; Turkington, RC; Virdee, PS | 1 |
| Tang, C; Wu, J; Xu, J | 1 |
| Deng, BB; Jiao, BP; Li, YR; Liu, YJ; Wang, GJ | 1 |
| Karamouzis, MV; Koustas, E; Papavassiliou, AG; Sarantis, P; Schizas, D | 1 |
| Chan, MWY; Chang, TS; Chen, WM; Chiang, MK; Hsieh, YY; Lu, CK; Tung, SY; Wei, KL; Wu, CS | 1 |
| Cao, F; Gao, WB; Guo, XC; Pan, L; Zhang, YH; Zhu, HJ | 1 |
| Kang, W; Kwon, JY; Lee, C; Lee, H; Maher, L; Michaud, M; Ning, G; Silva, M; Suh, YS; Zhang, C; Zhu, Q | 1 |
| Chang, MS; Choi, Y; Jang, BG; Kim, MA; Kim, Y; Ko, YS; Lee, BL; Lee, JS; Park, J; Park, JW; Pyo, JS | 1 |
| Bai, M; Che, X; Liu, Y; Qu, X; Song, N; Wang, X | 1 |
| Ding, C; Jiao, XD; Yu, G; Zang, YS | 1 |
| Gong, L; Liu, J; Qian, Z; Song, G; Xu, J | 1 |
| Liu, H; Song, Q; Yang, Y; Yu, X; Yu, Y | 1 |
| Guo, J; Guo, T; Liu, D; Sun, Y; Wang, N; Zhu, X | 1 |
| Chi, Y; Jiang, ZC | 1 |
| Deng, X; Jiang, X; Liu, G; Wang, C; Wang, R; Xin, H; Yuan, C; Zhu, Y | 1 |
| He, J; Liu, F; Qi, Z; Wang, Z; Yang, Y; Zhang, X; Zhao, G | 1 |
| Bang, YJ; Cho, JY; Han, HS; Jung, SA; Kim, JS; Kim, TY; Kim, YH; Lee, KH; Lee, KW; Lee, N; Park, SH; Park, YI; Rha, SY; Song, EK; Zang, DY | 1 |
| Rongrong, S; Sun, S; Xiaowu, L; Yangmei, Z; Youwei, Z; Yuan, Y | 1 |
| Hattori, S; Kage, M; Kan, H; Kawahara, A; Kuwano, M; Murakami, Y; Ono, M; Shibata, T; Ureshino, H; Watari, K | 1 |
| Atoyan, R; Cai, X; Lai, CJ; Ma, AW; Pursell, NW; Samson, ME; Savagner, P; Selmi, A; Voi, M; Wang, J; Xu, W | 1 |
| Boku, N | 1 |
| Carbonetti, G; Carlin, SD; Chiosis, G; de Stanchina, E; Divilov, V; Gomes-DaGama, EM; Holland, JP; Janjigian, YY; Lewis, JS; Viola-Villegas, N | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
| Bang, YJ; Han, SW; Hwang, D; Im, SA; Jeong, EG; Kim, HP; Kim, TY; Lee, MY; Song, SH | 1 |
| Furuya, T; Ito, Y; Kodera, Y; Kondo, E; Murakami, H; Nakanishi, H; Oshima, Y; Tanaka, H | 1 |
| Liu, Y; Shi, HL; Wu, XJ; Xie, JQ | 1 |
| Chang, CM; Chang, WC; Chuang, HY; Hou, MF; Lee, YC; Lin, YC; Tsai, YT; Wang, JY; Wei, PL; Wong, JH | 1 |
| Sato, Y; Takakura, N; Yashiro, M | 1 |
| Fujii, H; Izawa, S; Kiessling, R; Kono, K; Kua, LF; Mimura, K; Mueller, A; Seliger, B; Shiraishi, K; So, J; Yong, WP | 1 |
| Bi, Y; Huang, H; Liu, X; Ran, G; Wu, D; Yang, L; Zhang, M | 1 |
| Gavine, P; Gu, Y; Liu, C; Liu, YJ; Lv, J; Ni, X; Qian, J; Qian, Z; Shen, D; Su, X; Sun, Y; Xu, Y; Yin, X; Zhan, P; Zhang, J; Zhang, T | 1 |
| Fukami, K; Ito, Y; Kamata, R; Sakai, R; Takanashi, M; Yamaguchi, H; Yanagihara, K; Yoshida, N | 1 |
| Chen, Y; Feng, Z; He, Q; Liang, C; Meng, L; Shu, M; Yang, D; Yu, K; Zhao, H | 1 |
| Chen, XG; Jin, J; Wang, TE; Wang, YK; Xu, BL | 1 |
| Bang, YJ; Chung, HC; Chung, IJ; Doi, T; Feng, JF; Kobayashi, M; Li, J; Miwa, H; Mukaiyama, A; Ohtsu, A; Omuro, Y; Qin, SK; Satoh, T; Sun, GP; Tsuji, A; Wang, JW; Xu, JM; Xu, RH; Yeh, KH | 1 |
| Chiou, SK; Ge, L; Hoa, N; Hodges, A; Jadus, MR | 1 |
| Dong, CS; Li, JH; Liu, QL; Liu, RJ; Luo, BH; Luo, GQ; Wang, JP; Wang, KS; Wen, JF; Xiao, H; Xiao, N; Xie, B; Xiong, F; Yang, XJ; Zhong, M | 1 |
| Chang, J; Fang, Q; Geng, R; Ji, D; Li, J; Liu, L; Liu, R; Wang, C; Wang, J; Wu, Z; Xiong, L; Zhang, Z; Zhu, D | 1 |
| Chen, YX; Geng, HY; Qin, SK; Wang, L; Xu, HJ; Xue, S; Yang, AZ | 1 |
| Bass, AJ; Fox, C; Hong, SW; Hong, YS; Kim, J; Ma, Q; Pectasides, E; Peng, S; Stachler, MD; Thorner, AR; Van Hummelen, P; Wong, GS | 1 |
| Hu, C; Li, W; Ma, JA; Ren, J; Wei, Y; Zhou, D; Zhou, Y; Zou, F; Zou, W | 1 |
| Ali, SM; Chmielecki, J; Frampton, GM; Lipson, D; Miller, VA; Morosini, D; Palma, N; Palmer, GA; Ross, JS; Stephens, PJ; Wang, K; Yelensky, R | 1 |
| Ding, Z; Tang, L; Zhao, P; Zhou, X | 1 |
| Han, YF; Lin, X; Wu, LQ; Zhang, QY; Zhang, T | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Jia, Y; Sun, T; Xiao, D | 1 |
| Banno, E; Boku, N; De Velasco, MA; Fujita, Y; Mizukami, T; Nakajima, TE; Nishio, K; Sakai, K; Sogabe, S; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Cheng, J; He, XJ; Li, C; Wang, CH; Wang, YH; Ye, ZJ; Zeng, H | 1 |
| Ding, P; Guo, Q; Jiang, Z; Li, H; Sun, L; Tian, C; Wang, Z; Yuan, Z; Zhang, L; Zhao, Y | 1 |
| Cheow, H; De Silva, N; Fitzgerald, R; Ford, H; Godfrey, E; Hochhauser, D; Jobanputra, M; Lao-Sirieix, P; O'Donovan, M; Paterson, A; Qain, W; Schulz, L; Secrier, M | 1 |
| Feng, S; Hong, D; Wang, Q; Wang, Z; Wei, L; Wen, Z | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Bi, Y; Huang, H; Liu, X; Wang, LH; Yang, L | 1 |
| Duan, H; Han, Y; Huang, D; Huang, H; Qu, L; Ru, G; Shou, C; Tong, X; Zhao, Z | 1 |
| Kubo, T; Morimoto, K; Sato, Y; Seyama, T; Yanagihara, K | 1 |
| Allemand, DH; Charreau, EH; Cidlowski, JA; Cordo Russo, RI; Cortese, E; De Martino, M; Elizalde, PV; Guzmán, P; Huang, TH; Izzo, F; Mercogliano, MF; Oakley, RH; Pereyra, MG; Proietti, CJ; Rivas, MA; Roa, JC; Schillaci, R; Venturutti, L; Yankilevich, P | 1 |
| Gao, X; Guo, Q; Han, Y; Hu, C; Liu, M; Wang, J; Wang, Y; Zhang, K | 1 |
| Briner, C; Gladkov, O; Hsieh, RK; Kaneko, T; Koch, KM; LaBonte, MJ; Lee, WP; Lenz, HJ; Nagarwala, YM; Pishvaian, MJ; Rha, SY; Sakaeva, D; Urba, SG; Wilson, PM; Yang, D; Zhang, W | 1 |
| Apicella, M; Capelôa, T; Cargnelutti, M; Casorzo, L; Cassoni, P; Comoglio, PM; Corso, S; De Simone, M; Degiuli, M; Giordano, S; Marsoni, S; Menegon, S; Migliore, C; Sapino, A; Sarotto, I; Sottile, A | 1 |
| Ma, L; Qian, J; Shu, Y; Wang, Q; Wang, S; Xu, T; Yang, F; Zhou, J; Zhu, W | 1 |
| Afenjar, K; Bang, YJ; Chu, MP; Chua, N; Hecht, JR; Hiller, JP; Hoff, PM; Houe, V; Huang, YJ; Khan-Wasti, S; King, K; Koski, S; Mulder, K; Qin, S; Sawyer, MB; Scarfe, A; Slamon, D; Sobrero, A; Spratlin, J; Wainberg, ZA | 1 |
| Chiba, Y; Haratani, K; Hayashi, H; Kawakami, H; Nakagawa, K; Nonagase, Y; Takahama, T; Takeda, M; Takegawa, N; Tamura, T; Tanizaki, J; Tsurutani, J; Ueda, H; Watanabe, S; Yonesaka, K; Yoshida, T | 1 |
| Matsuhashi, N; Matsui, S; Okumura, N; Osada, S; Sasaki, Y; Takahashi, T; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yawata, K; Yoshida, K | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Ellis, CE; Estrada, MC; Gagnon, RC; Grob, TJ; Hecht, JR; Jeziorski, K; Liang, Z; Ma, Y; Park, JO; Press, MF; Qin, SK; Robinson, DM; Sauter, G; Scherer, SJ; Slamon, DJ; Villalobos, I; Wu, S; Xu, J | 1 |
| Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, TY; Oh, DY; Yoon, YK | 1 |
| Hede, K | 1 |
| Teng, KY; Xu, RH | 1 |
| Galle, PR; Gockel, I; Heidel, F; Lang, H; Lyros, O; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Chen, Z; Ding, WB; Lou, YJ; Ye, ZQ; Yu, YP; Zhang, YD | 1 |
| Anghel, A; Ayala, R; Desai, AJ; Fejzo, MS; Finn, RS; Hecht, JR; Luo, T; Safran, B; Slamon, DJ; Wainberg, ZA | 1 |
| Jørgensen, JT | 1 |
| Fukuoka, M; Kiniwa, M; Nakagawa, K; Okamoto, I; Takezawa, K; Tanizaki, J; Tsukioka, S; Uchida, J | 1 |
| Cunningham, D; Okines, AF | 1 |
| Li, RK; Liao, J; Qiang, O; Wang, CH | 1 |
| Catalano, G; Ciardiello, F; De Vita, F; Giuliani, F; Orditura, M; Silvestris, N | 1 |
| He, S; Huang, H; Huang, Y; Li, Z; Liu, X; Xu, W; Zhang, H; Zhang, Y | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Nam, HJ; Oh, DY; Song, SH; Yoon, YK | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T | 1 |
| Alcindor, T; Au, HJ; Jarvi, A; MacAlpine, K; Mackay, HJ; McWhirter, E; Oza, AM; Wang, L; Wright, JJ | 1 |
| Blanke, CD; Danenberg, KD; Fenoglio-Preiser, CM; Goldman, B; Iqbal, S; Lenz, HJ; Shibata, SI; Zhang, W | 1 |
| Belkhiri, A; El-Rifai, W; Zhu, S | 1 |
| Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y | 1 |
| Dasanu, CA; Kaur, A | 1 |
| Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Aoki, Y; Fujii, T; Hada, K; Ishii, N; Kondoh, O; Mio, T; Miura, T; Nakanishi, Y; Nakano, K; Ono, N; Saitoh, R; Sakata, K; Sato, S; Suda, A; Tachibana, Y; Tsukuda, T; Yamazaki, T | 1 |
| Cheng, M; Guo, Q; Li, F; Peng, H; Wang, J; Wang, Y; Zhang, J; Zhao, D; Zhou, Y | 1 |
| Chen, CT; Christensen, JG; Gao, S; Kim, H; Liska, D; Weiser, MR | 1 |
| Chen, LQ; Gao, Q; Wang, KN; Wang, WP | 1 |
| Khan, M; Ma, T; Rasul, A; Yang, H; Yu, B; Zhong, L | 1 |
| Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yu, L; Zou, Z | 1 |
| Ekyalongo, RC; Fujiwara, Y; Funakoshi, Y; Imai, Y; Kataoka, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H | 1 |
| Adelstein, DJ; Ives, DI; Phillips, BE; Plesec, T; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Tubbs, RR; Videtic, GM | 1 |
| Kołodziejczyk, P; Kulig, J; Kulig, P; Legutko, J | 1 |
| Bang, YJ; Elvin, P; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, A; Nam, HJ; Oh, DY; Song, SH; Yoon, YK | 1 |
| Fujii, H; Inoue, A; Inoue, M; Izawa, S; Kawaguchi, Y; Kono, K; Maruyama, T; Mimura, K; Shiba, S; Shiraishi, K; Watanabe, M | 1 |
| Kassis, J; Klein, G; Maeda, A; Takada, K; Teramoto, N; Wells, A; Wu, C | 1 |
| Blanco, Cdel V; Caputo, R; Ciardiello, F; Manzo, BA; Ricci, V; Romano, M; Tortora, G; Tuccillo, C; Zarrilli, R | 1 |
| Boige, V; Ducreux, M | 1 |
| Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, KE; Schüll, B | 1 |
| Aiba, K; Horikoshi, N; Koizumi, W; Sasaki, T; Sato, A | 1 |
| Petruzelka, L | 1 |
| Bucana, C; Ellis, LM; Fan, F; Liu, W; Mansfield, PF; McCarty, MF; Ryan, AJ; Stoeltzing, O; Wey, J | 1 |
| Kang, JH; Kuh, HJ; Lee, SH; Nishio, K; Park, JK; Saijo, N | 1 |
| Bjarnason, GA; Charpentier, D; Dent, S; Douglas, L; Goel, R; Matthews, S; Seymour, L; Walsh, W; Winquist, E; Wong, R | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Amoroso, V; Ferrari, VD; Fusi, A; Mambrini, A; Marini, G; Marpicati, P; Montini, E; Rangoni, G; Simoncini, E; Valcamonico, F; Vasalli, L | 1 |
| Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 2 |
| Bao, Y; Ding, YB; Li, XY; Shi, RH; Tong, JD; Wang, XH; Wu, J; Xiao, WM; Yan, ZG; Yang, JG; Zhang, GX | 1 |
| Arao, T; Koizumi, F; Nishio, K; Shiratori, Y; Takeda, M; Takigahira, M; Yanagihara, K | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Date, M; Fujise, K; Matsumoto, K; Nakamura, T; Namiki, T; Namiki, Y; Satoi, J; Tada, N; Yanagihara, K; Yashiro, M; Yoshida, H | 1 |
| Kitayama, J; Mori, K; Nagawa, H; Shida, D; Watanabe, T | 1 |
| Barnard, GF; Ishii, H; Mimori, K; Mori, M; Nagahara, H; Sudo, T; Yamashita, K | 1 |
| Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H | 1 |
| Becker, JC; Berdel, WE; Brandts, C; Domschke, W; Fujimori, T; Ilea, AM; Müller-Tidow, C; Pohle, T; Serve, H; Stolte, M; Tickenbrock, L; Tidow, N | 1 |
| Ajani, J; Albert, D; Anthoney, A; Chick, J; Drolet, DW; Eatock, M; Falk, S; Ferry, D; Glen, H; Valle, JW; Van Cutsem, E | 1 |
| Albanell, J; Baselga, J; Doi, T; Koizumi, W; Ohtsu, A; Ramon Cajal, S; Ramon y Cajal, S; Rojo, F; Shirao, K; Tabernero, J; Takiuchi, H; Van Cutsem, E | 1 |
| Abbruzzese, JL; Baker, AF; Benedetti, JK; Blanke, CD; Dragovich, T; Fenoglio-Preiser, CM; Hackett, CB; McCoy, S; Urba, SG; Wang, J; Zaner, KS | 1 |
| Fujiwara, M; Ikehara, S; Ikehara, Y; Kodera, Y; Koike, M; Mochizuki, Y; Nakanishi, H; Nakao, A; Tatematsu, M; Yatabe, Y; Yokoyama, H | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Personeni, N | 1 |
| Arao, T; Fukuoka, K; Kimura, H; Komatsu, T; Nishio, K; Saijo, N; Sasaki, H; Takeda, M; Tamura, T; Yamada, Y; Yanagihara, K; Yokote, H | 1 |
| Cao, WG; Chen, XH; Ji, YB; Jin, YN; Li, H; Li, JF; Liu, BY; Ma, T | 1 |
| Douglass, HO; Kelsen, DP; Meropol, NJ; Pazdur, R; Vincent, M; Willson, JK | 1 |
| Anthony, DA; Eatock, MM; El-Abassi, M; Evans, TR; Paul, J; Smith, M; Soukop, M; Wilson, P | 1 |
| Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M | 1 |
6 review(s) available for quinazolines and Cancer of Stomach
| Article | Year |
|---|---|
HER2-positive gastric cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2014 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Esophageal Neoplasms; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Targeted therapy for gastric cancer--current status.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drugs, Investigational; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab | 2006 |
24 trial(s) available for quinazolines and Cancer of Stomach
| Article | Year |
|---|---|
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prospective Studies; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2019 |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Odds Ratio; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome | 2014 |
Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Double-Blind Method; Female; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Seeding; Prospective Studies; Quinazolines; Stomach Neoplasms; Thiophenes | 2014 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Lapatinib; Male; MAP Kinase Signaling System; Middle Aged; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2015 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Disease Progression; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Neoplasm Staging; Polymorphism, Single Nucleotide; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Treatment Outcome | 2016 |
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Interactions; Esophageal Neoplasms; Female; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proton Pump Inhibitors; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2017 |
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome; Young Adult | 2017 |
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Benzodioxoles; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Stomach Neoplasms | 2012 |
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Hyponatremia; Japan; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Oxonic Acid; Quinazolines; Stomach Neoplasms; Tegafur; Treatment Outcome; Tumor Burden | 2012 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cohort Studies; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2013 |
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Retreatment; Salvage Therapy; Stomach Neoplasms; Survival Rate; Thiophenes | 2003 |
Phase I dose-escalation trial of ZD9331 in Japanese patients with refractory, solid malignancies.
Topics: Adult; Colorectal Neoplasms; Drug Tolerance; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Quinazolines; Stomach Neoplasms | 2003 |
Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer.
Topics: Abdominal Pain; Antineoplastic Agents; Diarrhea; Drug Tolerance; Hematologic Diseases; Humans; Multicenter Studies as Topic; Neutropenia; Quinazolines; Stomach Neoplasms; Thymidylate Synthase | 2003 |
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Salvage Therapy; Stomach Neoplasms; Thiophenes | 2005 |
Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Epirubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Survival Analysis; Thiophenes | 2004 |
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Glutarates; Humans; Isoindoles; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Area Under Curve; Biomarkers, Tumor; Carcinoma; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Stomach Neoplasms | 2006 |
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Topics: Biomarkers, Tumor; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of ZD1694 in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Asthenia; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mucous Membrane; Nausea; Neoplasm Staging; Quinazolines; Remission Induction; Stomach Neoplasms; Thiophenes; Thrombocytopenia; Thymidylate Synthase; Vomiting | 1996 |
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Thiophenes; Treatment Outcome | 2000 |
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome | 2001 |
107 other study(ies) available for quinazolines and Cancer of Stomach
| Article | Year |
|---|---|
Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2022 |
BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Humans; MAP Kinase Signaling System; Membrane Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pyrans; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Stomach Neoplasms | 2022 |
Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.
Topics: Benzamides; Cell Line, Tumor; Humans; Kinesins; Quinazolines; Stomach Neoplasms | 2023 |
Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by upregulating RSK4.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Quinazolines; Stomach Neoplasms; Thiophenes | 2022 |
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Paclitaxel; Quinazolines; Stomach Neoplasms | 2023 |
Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; RNA, Long Noncoding; SOXB1 Transcription Factors; Stomach Neoplasms | 2023 |
G9a promotes cell proliferation and suppresses autophagy in gastric cancer by directly activating mTOR.
Topics: Animals; Autophagy; Azepines; Cell Cycle; Cell Line; Cell Proliferation; Cell Survival; Down-Regulation; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Histones; Humans; Mice, SCID; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2019 |
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Esophageal Neoplasms; Esophagogastric Junction; Exanthema; Fatigue; Female; Humans; Male; Margins of Excision; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Stomach Neoplasms; Vomiting | 2020 |
Effect of isofebrifugine on the proliferation and invasion of human gastric cancer cells via MMP.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Piperidines; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2020 |
BIX-01294 enhanced chemotherapy effect in gastric cancer by inducing GSDME-mediated pyroptosis.
Topics: Animals; Apoptosis; Autophagy; Azepines; Cell Death; Cell Line, Tumor; Cell Survival; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pyroptosis; Quinazolines; Stomach Neoplasms | 2020 |
Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Clone Cells; DNA Damage; Histones; Humans; Indoles; Mice; Models, Biological; Neoplasm Proteins; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Stomach Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
2,4-Diamino-Quinazoline, a Wnt Signaling Inhibitor, Suppresses Gastric Cancer Progression and Metastasis.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Axin Protein; Cell Line; Cell Line, Tumor; Cells, Cultured; Female; Humans; Lymphoid Enhancer-Binding Factor 1; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins c-myc; Quinazolines; Receptors, G-Protein-Coupled; Stomach Neoplasms; Wnt Signaling Pathway | 2020 |
Absolute Configurations and Chitinase Inhibitions of Quinazoline-Containing Diketopiperazines from the Marine-Derived Fungus
Topics: Cell Line, Tumor; Chitinases; Circular Dichroism; Diketopiperazines; Enzyme Inhibitors; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Penicillium; Prazosin; Quinazolines; Stomach Neoplasms; Urinary Bladder Neoplasms | 2020 |
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidines; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Humans; Lapatinib; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Transfection; Up-Regulation | 2018 |
Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2018 |
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Capecitabine; Diagnostic Imaging; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Meningeal Carcinomatosis; Multimodal Imaging; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2018 |
ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway.
Topics: Acrylamides; Animals; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-4; Signal Transduction; Stomach Neoplasms; Survival Analysis; Up-Regulation | 2018 |
miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; MicroRNAs; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms | 2018 |
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.
Topics: Adult; Aged; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Stomach Neoplasms; Vascular Endothelial Growth Factor A | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cesarean Section; China; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate; Thiophenes | 2018 |
IFT80 Improves Invasion Ability in Gastric Cancer Cell Line via ift80/p75NGFR/MMP9 Signaling.
Topics: Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cilia; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Nerve Tissue Proteins; Quinazolines; Receptors, Nerve Growth Factor; Signal Transduction; Stomach Neoplasms | 2018 |
Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells.
Topics: Aurora Kinase B; Case-Control Studies; Cell Line, Tumor; Dose-Response Relationship, Drug; Glucose; Glucose Transporter Type 1; Humans; Isoenzymes; L-Lactate Dehydrogenase; Organophosphates; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Ribosomal Proteins; Stomach Neoplasms | 2019 |
Sotrastaurin attenuates the stemness of gastric cancer cells by targeting PKCδ.
Topics: Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Neoplastic Stem Cells; Protein Kinase C-delta; Pyrroles; Quinazolines; Stomach Neoplasms | 2019 |
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Y-Box-Binding Protein 1 | 2013 |
Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Topics: Afatinib; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Humans; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiochemistry; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Topics: beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; G1 Phase; Humans; Lapatinib; Proteoglycans; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Transcription, Genetic; Up-Regulation | 2014 |
Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Mucin-4; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2014 |
[Chinese expert consensus on the molecular-targeted therapy for HER-2-positive advanced gastric cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Consensus; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2013 |
Berberine counteracts enhanced IL-8 expression of AGS cells induced by evodiamine.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Chemokines; Chemokines, CXC; Chromones; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-8; Morpholines; Pyridines; Quinazolines; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured | 2013 |
Pb²⁺ induced IL-8 gene expression by extracellular signal-regulated kinases and the transcription factor, activator protein 1, in human gastric carcinoma cells.
Topics: Cell Line, Tumor; Environmental Pollutants; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Interleukin-8; Lead; Proto-Oncogene Proteins c-jun; Quinazolines; Stomach Neoplasms; Transcription Factor AP-1; Tyrphostins; Up-Regulation | 2015 |
Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; Lapatinib; Neuregulin-1; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2013 |
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
Topics: Androstadienes; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; HLA-A Antigens; Humans; Lapatinib; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Wortmannin | 2013 |
Growth inhibition and induction of apoptosis in SGC‑7901 human gastric cancer cells by evodiamine.
Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Shape; Humans; Quinazolines; Stomach Neoplasms | 2014 |
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Peritoneum; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; src-Family Kinases; Stomach Neoplasms | 2014 |
A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Glioma; Humans; Inhibitory Concentration 50; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Pyridazines; Pyridones; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescent Antibody Technique; G2 Phase Cell Cycle Checkpoints; Humans; In Situ Nick-End Labeling; M Phase Cell Cycle Checkpoints; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Stomach Neoplasms | 2014 |
Indomethacin promotes apoptosis in gastric cancer cells through concomitant degradation of Survivin and Aurora B kinase proteins.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aurora Kinase B; Carcinoma; Cell Line, Tumor; Gastric Mucosa; Humans; Indomethacin; Inhibitor of Apoptosis Proteins; Mice, Inbred C57BL; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms; Survivin | 2014 |
Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; EGF Family of Proteins; Endothelial Growth Factors; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Signal Transduction; Snail Family Transcription Factors; Stomach Neoplasms; Transcription Factors; Tyrphostins; Vimentin | 2014 |
Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Topics: Antigens, CD; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Middle Aged; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Stomach Neoplasms | 2014 |
Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cytochromes c; G1 Phase Cell Cycle Checkpoints; Humans; Membrane Potential, Mitochondrial; Mitochondria; Oligopeptides; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Thiophenes; Thymidylate Synthase | 2014 |
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; Stomach Neoplasms | 2014 |
Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitory Concentration 50; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Transfection | 2015 |
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; DNA Copy Number Variations; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2015 |
Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Survival; Cytoplasm; Enzyme Activation; Extracellular Fluid; Gefitinib; HMGB1 Protein; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor for Advanced Glycation End Products; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Transfection | 2015 |
Interference of STAT 5b expression enhances the chemo-sensitivity of gastric cancer cells to gefitinib by promoting mitochondrial pathway-mediated cell apoptosis.
Topics: Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; STAT5 Transcription Factor; Stomach Neoplasms | 2015 |
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2015 |
Antitumor quinazoline alkaloids from the seeds of Peganum harmala.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Glucosides; Humans; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Peganum; Quinazolines; Seeds; Stomach Neoplasms | 2015 |
A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; ErbB Receptors; G1 Phase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Resting Phase, Cell Cycle; Signal Transduction; Stomach Neoplasms | 2015 |
Evodiamine, a novel inhibitor of the Wnt pathway, inhibits the self-renewal of gastric cancer stem cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Epithelial-Mesenchymal Transition; Flow Cytometry; Humans; Kruppel-Like Factor 4; Molecular Structure; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Quinazolines; Snail Family Transcription Factors; Stomach Neoplasms; Transcription Factors; Twist-Related Protein 1; Wnt Signaling Pathway | 2015 |
[Effect of evodiamine in inducing apoptosis of gastric cancer SGC-7901 cells through mTOR signal pathway].
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drugs, Chinese Herbal; Humans; Quinazolines; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2015 |
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Snail Family Transcription Factors; Stomach Neoplasms; Survival Analysis; Up-Regulation | 2016 |
High mannose-binding Pseudomonas fluorescens lectin (PFL) downregulates cell surface integrin/EGFR and induces autophagy in gastric cancer cells.
Topics: Animals; Autophagy; Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Integrins; Mannose-Binding Lectin; Mice; Pseudomonas fluorescens; Quinazolines; RNA, Small Interfering; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclins; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lapatinib; Male; Mice; MicroRNAs; Models, Biological; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA-Binding Proteins; Stomach Neoplasms; Trastuzumab | 2016 |
Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Immunohistochemistry; Male; Mice; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Membrane Transport Proteins; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2016 |
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Topics: Ado-Trastuzumab Emtansine; Aged; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Male; Maytansine; Middle Aged; Neuregulin-1; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms; Survivin; Trastuzumab | 2016 |
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Female; Fluorouracil; Humans; Mice; Mice, Nude; Piperidines; Quinazolines; Stomach Neoplasms; Thymidylate Synthase; Tumor Burden | 2016 |
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Stomach Neoplasms | 2009 |
Gastric cancer: trastuzumab trial results spur search for other targets.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Everolimus; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Receptor, ErbB-2; Sirolimus; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2009 |
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; ErbB Receptors; Esophageal Neoplasms; Flow Cytometry; Humans; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Sunitinib; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
[4, 8-disubstituted-8, 9-dihydro-pyrazine[2,3-g]quinazoline-7(6H)-ketones: a novel class of antitumor agents].
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; K562 Cells; Lung Neoplasms; Molecular Structure; Pyrazines; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2010 |
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Combinations; Drug Delivery Systems; Drug Synergism; Fluorouracil; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Trastuzumab in gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Forecasting; Genes, erbB-2; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
[Effects of EGFR inhibitor AG1478 in combination with celecoxib on the growth of gastric cancer cells].
Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Humans; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proliferating Cell Nuclear Antigen; Pyrazoles; Quinazolines; Stomach Neoplasms; Sulfonamides; Tyrphostins | 2010 |
Acid sphingomyelinase contributes to evodiamine-induced apoptosis in human gastric cancer SGC-7901 cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Ceramides; Chromatography, High Pressure Liquid; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Plant Extracts; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sphingomyelin Phosphodiesterase; Sphingomyelins; Stomach Neoplasms; Up-Regulation | 2011 |
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Phosphorylation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2011 |
Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab.
Topics: Abdominal Pain; Adenocarcinoma, Papillary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Immunohistochemistry; Lapatinib; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2011 |
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2011 |
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms | 2011 |
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Topics: Actin Depolymerizing Factors; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lim Kinases; MAP Kinase Kinase 1; Matrix Metalloproteinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Molecular; Molecular Structure; Neoplasm Invasiveness; p21-Activated Kinases; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pseudopodia; Quinazolines; Signal Transduction; Stomach Neoplasms; Structure-Activity Relationship; Transfection | 2012 |
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Stomach Neoplasms; Sulfones | 2012 |
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate | 2012 |
Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated X Protein; Beclin-1; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Stomach Neoplasms | 2012 |
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship | 2012 |
Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Female; Humans; Male; Middle Aged; Quinazolines; RNA, Messenger; Stomach Neoplasms; Thiophenes; Thymidylate Synthase | 2012 |
Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gene Amplification; Humans; Paclitaxel; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Trastuzumab | 2012 |
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Female; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Expression; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Tumor Cells, Cultured | 2013 |
EBV-expressing AGS gastric carcinoma cell sublines present increased motility and invasiveness.
Topics: Carcinoma, Signet Ring Cell; Cell Movement; Collagen; Drug Combinations; Enzyme Inhibitors; ErbB Receptors; Estrenes; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Herpesvirus 4, Human; Humans; Integrins; Isoenzymes; Laminin; Neoplasm Invasiveness; Phospholipase C gamma; Phosphorylation; Protein-Tyrosine Kinases; Proteoglycans; Pyrrolidinones; Quinazolines; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured; Type C Phospholipases | 2002 |
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism.
Topics: Bacterial Proteins; Cyclooxygenase 2; ErbB Receptors; Gefitinib; Helicobacter pylori; Humans; Isoenzymes; MAP Kinase Signaling System; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Quinazolines; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Up-Regulation; Vascular Endothelial Growth Factor A | 2003 |
Treatment of advanced gastric cancer: where we are in 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Thiophenes; Treatment Outcome | 2003 |
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Capillaries; Cell Proliferation; Endothelial Cells; ErbB Receptors; Humans; Mice; Neovascularization, Pathologic; Pericytes; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Stomach Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Base Pair Mismatch; Carrier Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Fluorouracil; Formazans; G1 Phase; G2 Phase; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Models, Biological; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Stomach Neoplasms; Tetrazolium Salts | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system.
Topics: Calcium-Calmodulin-Dependent Protein Kinases; Dinoprostone; Enzyme Inhibitors; ErbB Receptors; Flavonoids; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinase 1; Oxytocics; Phosphorylation; Quinazolines; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Transcriptional Activation; Tumor Cells, Cultured; Tyrphostins; Up-Regulation; Vascular Endothelial Growth Factor A | 2005 |
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
Topics: Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Peritoneal Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Adult; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Genetic Therapy; Hepatocyte Growth Factor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneum; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells.
Topics: Cell Line, Tumor; Dipeptides; ErbB Receptors; Humans; Janus Kinase 2; Leptin; MAP Kinase Signaling System; Metalloproteases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protease Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; Receptors, Cell Surface; Receptors, Leptin; Recombinant Proteins; Stomach Neoplasms; Transcriptional Activation; Tyrphostins | 2005 |
The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Female; Gefitinib; Genes, erbB-1; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms | 2006 |
Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Blotting, Western; Cell Survival; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Humans; Middle Aged; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
Topics: ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2007 |
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dimerization; Gefitinib; Humans; Mice; Mice, Inbred Strains; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Stomach Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2007 |
[Effect of gefitinib on radiosensitivity of gastric cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Particle Accelerators; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Stomach Neoplasms | 2007 |